Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plixorafenib PK and Safety Study with Food and Cobicistat in Healthy Participants
NCT06385119Phase 1Completed
- Sponsor
- Fore Biotherapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of plixorafenib in solid tumor (7 arms), sponsored by Fore Biotherapeutics. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration and 8 more. Started Apr 2024; status: completed.
02
Drugs
plixorafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06385119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385119.